“We are pleased to report strong second quarter results that delivered double-digit sales growth. Based on our better-than-expected first half performance and the many catalysts across our portfolio, ...

Edwards’ financials reveal that its transcatheter mitral and tricuspid therapies (TMTT) portfolio grew by 56.4% in 2025.

Edwards Lifesciences’ (NYSE:EW) stock surged Friday following a strong second-quarter 2025 earnings report that saw the medical device innovator surpass revenue and earnings expectations, driven by ...

Edwards Lifesciences Corporation remains a market leader in transcatheter heart valve technologies, with strong secular tailwinds and consistent revenue growth. EW's TMTT segment is the ...

Innovation with Purpose, Powered by Science, Centered on Patients: Edwards’ Commitment to Drive Value for the Healthcare Ecosystem IRVINE, Calif.--(BUSINESS WIRE)-- Edwards Lifesciences (EW) will ...

Edwards' Q4 EPS lags estimates but revenues top as TAVR and TMTT surge. Shares rise with 2026 sales growth seen at 8%-10%.

Edwards Lifesciences Corp. EW is scheduled to report second-quarter 2025 results on July 24, after market close. In the last reported quarter, the company’s adjusted earnings per share of 64 cents ...

Edwards Lifesciences (NYSE: EW) will outline its patient-focused strategy and share financial guidance during its annual investor conference. Entering 2026 with momentum for sustainable differentiated ...